Assignee
PHILOGEN SPA
IT·34 granted patents·26 pending applications·97 citations·filing 1997–2023
Top patents by PatentIndex Score
60 records- 0190US10308696B2IL2 and TNF immunoconjugatesPHILOGEN SPA·Filed 2016·Granted Jun 4, 2019·12 cites·20 claims
- 0287US7968685B2Antibodies against Tenascin-CPHILOGEN SPA·Filed 2005·Granted Jun 28, 2011·24 cites·14 claims
- 0383US9446124B2Targeting of bone marrow neovasculaturePHILOGEN SPA·Filed 2014·Granted Sep 20, 2016·3 cites·7 claims
- 0481US9181347B2Antigen associated with the neovasculature of tumour metastasesPHILOGEN SPA·Filed 2013·Granted Nov 10, 2015·4 cites·20 claims
- 0581US7851599B2Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabinePHILOGEN SPA·Filed 2007·Granted Dec 14, 2010·10 cites·20 claims
- 0680US11872288B2TNF-alpha immunoconjugate therapy for the treatment of brain tumorsPHILOGEN SPA·Filed 2021·Granted Jan 16, 2024·2 cites·16 claims
- 0779US9896503B2Antigen associated with the neovasculature of tumour metastasesPHILOGEN SPA·Filed 2015·Granted Feb 20, 2018·2 cites·21 claims
- 0878US9198979B2Thiazolidine linker for the conjugation of drugs to antibodiesPHILOGEN SPA·Filed 2013·Granted Dec 1, 2015·10 cites·10 claims
- 0972US9695232B2Anti-ED-A immunoconjugates for inflammatory bowel diseasePHILOGEN SPA·Filed 2012·Granted Jul 4, 2017·2 cites·11 claims
- 1072US7273924B1Antibodies to the ED-B domain of fibronectin, their construction and usesPHILOGEN SPA·Filed 1997·Granted Sep 25, 2007·24 cites·27 claims
- 1171US11351257B2Antibody compositionsPHILOGEN SPA·Filed 2017·Granted Jun 7, 2022·1 cites·22 claims
- 1271US9096670B2Antibodies of the ED-B domain of fibronectin, their construction and usesPHILOGEN SPA·Filed 2013·Granted Aug 4, 2015·1 cites·18 claims
- 1369US10647760B2Antibodies for treatment and diagnosis of inflammatory bowel diseasePHILOGEN SPA·Filed 2016·Granted May 12, 2020·1 cites·7 claims
- 1467US12023381B2Antibody compositionsPHILOGEN SPA·Filed 2022·Granted Jul 2, 2024·0 cites·20 claims
- 1566US2015010498A1Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic AgentsPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 1663US12377161B2TNF-alpha immunoconjugate therapy for the treatment of brain tumorsPHILOGEN SPA·Filed 2023·Granted Aug 5, 2025·0 cites·16 claims
- 1763US2011020224A1Apparatus and method for preparing medicines containing radioactive substancesPHILOGEN SPA·Filed 2009·Application pending·0 cites
- 1863US2025368738A1Anti-cd28 antibodiesPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 1963US2026069660A1Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancerPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 2062US11274133B2IL2 and TNF immunoconjugatesPHILOGEN SPA·Filed 2019·Granted Mar 15, 2022·0 cites·18 claims
- 2161US2025073239A1Combination of an immunocytokine comprising il-12 and a kinase inhibitorPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 2261US2015030536A1Antigen associated with lung cancers and lymphomasPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 2361US2021369857A1Il2 and tnf mutant immunoconjugatesPHILOGEN SPA·Filed 2021·Application pending·0 cites
- 2460US2019352384A1Antigen associated with rheumatoid arthritisPHILOGEN SPA·Filed 2019·Application pending·0 cites
- 2559US10385121B2Antigen associated with rheumatoid arthritisPHILOGEN SPA·Filed 2016·Granted Aug 20, 2019·0 cites·38 claims
- 2659US9289470B2Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpartPHILOGEN SPA·Filed 2014·Granted Mar 22, 2016·0 cites·29 claims
- 2758US2013266511A1Novel antigen associated with the neovasculature of tumour metastasesPHILOGEN SPA·Filed 2013·Application pending·0 cites
- 2857US11103592B2IL2 and TNF mutant immunoconjugatesPHILOGEN SPA·Filed 2017·Granted Aug 31, 2021·0 cites·13 claims
- 2957US10858411B2IL22 immunoconjugatesPHILOGEN SPA·Filed 2019·Granted Dec 8, 2020·0 cites·14 claims
- 3057US2014377780A1Vascular Tumor MarkersPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 3156US2025170262A1Il2 immunoconjuqate preparationPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 3256US2025161475A1Tnfalpha immunoconjugate preparationPHILOGEN SPA·Filed 2023·Application pending·0 cites
- 3355US2014348784A1Compositions and methods for treatment of angiogenesis in pathological lesionsPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 3454US10112992B2Antigens associated with endometriosis, psoriatic arthritis and psoriasisPHILOGEN SPA·Filed 2016·Granted Oct 30, 2018·0 cites·11 claims
- 3554US7109301B1Tenascin-C isoform as marker for neoplasiasPHILOGEN SPA·Filed 2000·Granted Sep 19, 2006·1 cites·12 claims
- 3654US2014341844A1Immunocytokines in combination with anti-erbb antibodies for the treatment of cancerPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 3754US2024199762A1Anti-fibroblast activation protein antibodiesPHILOGEN SPA·Filed 2022·Application pending·0 cites
- 3852US10906963B2Non-glycosylated anti-tenascin antibodyPHILOGEN SPA·Filed 2017·Granted Feb 2, 2021·0 cites·21 claims
- 3952US2013108581A1Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic AgentsPHILOGEN SPA·Filed 2012·Application pending·0 cites
- 4051US10239939B2Anti-ED-A immunoconjugates for inflammatory bowel diseasePHILOGEN SPA·Filed 2017·Granted Mar 26, 2019·0 cites·16 claims
- 4151US2009028793A1Vascular Tumor MarkersPHILOGEN SPA·Filed 2007·Application pending·0 cites
- 4249US11390666B2Vascular endothelial growth factor/anti-fibronectin antibody fusion proteinsPHILOGEN SPA·Filed 2018·Granted Jul 19, 2022·0 cites·4 claims
- 4349US10125190B2Anti-collagen antibodies for treatment and diagnosisPHILOGEN SPA·Filed 2015·Granted Nov 13, 2018·0 cites·15 claims
- 4448US2023285585A1Treatment of pulmonary hypertensionPHILOGEN SPA·Filed 2021·Application pending·0 cites
- 4547US12173044B2EDB targeting IL-12 compositionsPHILOGEN SPA·Filed 2019·Granted Dec 24, 2024·0 cites·13 claims
- 4647US10246502B2IL22 immunoconjugatesPHILOGEN SPA·Filed 2017·Granted Apr 2, 2019·0 cites·15 claims
- 4747US10202442B2Antigen associated with lung cancers and lymphomasPHILOGEN SPA·Filed 2016·Granted Feb 12, 2019·0 cites·26 claims
- 4847US10098976B2Antibodies for treatment and diagnosisPHILOGEN SPA·Filed 2015·Granted Oct 16, 2018·0 cites·20 claims
- 4944US2016200789A1Il4 conjugated to antibodies against extracellular matrix componentsPHILOGEN SPA·Filed 2014·Application pending·0 cites
- 5043US11629199B2Antibodies to tumour antigensPHILOGEN SPA·Filed 2018·Granted Apr 18, 2023·0 cites·14 claims
Showing the top 50 of 60 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →